An effective universal vaccine ideally providing broad protection against all influenza A virus (IAV) subtypes with pandemic or zoonotic potential circulating in animals, as well as against antigenically variable seasonal strains, remains an urgent public health need.
A study led by researchers at the Institut Curie and INSERM has identified a means of overcoming CD8+ T-cell exhaustion and loss of cytotoxic activity in tumors.
Classic galactosemia (CG) is an inborn error of galactose metabolism caused by a severe deficiency of galactose-1-phosphate:uridylyltransferase (GALT) enzymatic activity, which leads to accumulation of several metabolites such as galactose-1-phosphate (Gal-1-P), the substrate of GALT, and galactonate and galactitol, the oxidation and reduction products.
Sosei Group Corporation and AbbVie have entered a new drug discovery collaboration and option-to-license agreement to discover, develop and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR) targets associated with neurological disease.
Cellectis announced that the FDA has cleared its IND application to initiate a phase I/IIa clinical trial of UCART20x22 for patients with relapsed or refractory non-Hodgkin lymphoma (NHL).
Researchers from Alnylam Pharmaceuticals and collaborators published data from a study that aimed to identify novel therapeutic targets for abdominal obesity by searching for genetic variants associated with lower waist-to-hip ratio.
The Ontario Institute for Cancer Research (OICR), the University of Toronto and Sinai Health System have divulged thienyl and cycloalkyl aminopyrimidine compounds acting as NUAK family SNF1-like kinase inhibitors reported to be useful for the treatment of cancer and fibrosis.
RSS